Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024
27. Oktober 2024 08:15 ET
|
HeartFlow Holding, Inc.
— Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans for patients with coronary artery disease -– FFRCT further...
HeartFlow to Present Latest Data on AI-Enabled Coronary Artery Disease Management at TCT 2024
14. Oktober 2024 08:00 ET
|
HeartFlow Holding, Inc.
Long-term outcomes data from ADVANCE-DK Registry with HeartFlow FFRCT and Plaque Analysis and ongoing clinical studies highlighting CCTA and FFRCT diagnostic pathway to be discussed in six...
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
16. Juli 2024 12:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on...
HeartFlow's Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study
15. Mai 2024 12:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its...
HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients
08. Mai 2024 12:00 ET
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- In a groundbreaking development, a study published in the Journal of Vascular Surgery reveals for the first time that coronary CTA (CCTA) with...
HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography
12. März 2024 09:00 ET
|
HeartFlow Holding, Inc.
HeartFlow's non-invasive AI driven FFRCT predicts patient outcomes as effectively as the gold-standard invasive FFR out to 10 years MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) --...
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
18. Januar 2024 08:00 ET
|
Curonix LLC
Curonix Partners with Sure Med Compliance to Expand PNS Clinical Evidence
TCT 2023: HeartFlow Presents Clinical Data Featuring First Solution Offering Lesion-Specific Insights
25. Oktober 2023 11:00 ET
|
HeartFlow Holding, Inc.
New Clinical Data Support Use of Lesion-Specific FFRCT for Diagnosis and Treatment of Patients With Coronary Artery Disease
Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
04. Januar 2023 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), Dr. David Young, Processa Pharmaceuticals, CEO will present an update on Processa’s future therapeutic...
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
26. Januar 2022 08:15 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical stage company developing drugs for patients who have unmet...